Trung Huynh
Stock Analyst at UBS
(1.71)
# 1341
Out of 5,344 analysts
44
Total ratings
55.56%
Success rate
16.99%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
JSPR Jasper Therapeutics | Maintains: Buy | 38 33 | 4.79 | 588.94% | 2 | May 13, 2025 | |
CLDX Celldex Therapeutics | Maintains: Buy | 44 38 | 20.39 | 86.37% | 2 | May 9, 2025 | |
INSM Insmed | Maintains: Buy | 110 109 | 67.55 | 61.36% | 5 | May 9, 2025 | |
AMGN Amgen | Maintains: Neutral | 319 315 | 272.08 | 15.77% | 4 | May 2, 2025 | |
LLY Eli Lilly | Maintains: Buy | 1100 1050 | 713.52 | 47.16% | 8 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 768 633 | 588.66 | 7.53% | 2 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 24 25 | 23.32 | 7.2% | 6 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 60 54 | 46.91 | 15.11% | 5 | Apr 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 10 7 | 1.75 | 300% | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 13 | 2.27 | 472.69% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 170 175 | 153.06 | 14.33% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 125 126 | 77.57 | 62.43% | 3 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 170 | 183.52 | -7.37% | 1 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | n/a | n/a | n/a | 1 | Mar 23, 2021 |